New hope for younger AML patients: targeted therapy combo tested against standard care
NCT ID NCT06917911
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 32 times
Summary
This study tests whether a newer targeted drug (venetoclax) works as well or better than an older targeted drug (gemtuzumab ozogamicin) when both are added to standard chemotherapy for a specific type of acute myeloid leukemia called core binding factor AML. About 162 younger adults with newly diagnosed disease will take part. The goal is to see which combination leads to deeper remissions with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.